YOLFTbeta
Appili Therapeutics Inc

Appili Therapeutics Inc

APLI · TO · Healthcare / Biotechnology

0.005CAD-0.01 (-50.00%)

Price History

Full chart

Market Stats

Previous Close0.01
Open0.005
Day Range0.005 – 0.005
52-Week Range0.005 – 0.03
Volume117.00K
Market Cap661.83K
P/E (TTM)0.00
Forward P/E2.38
EPS-0.03
Dividend Yield0.00%
Beta-0.19
50-Day Avg0.0114
200-Day Avg0.0165

About

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection. The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Donald D. Cilla Jr., M.B.A., Pharmd
  • Employees7
  • Headquarters1344 Summer Street, Halifax, NS, Canada, B3H 0A8, Canada
  • Websitehttps://appilitherapeutics.com

Leadership

  • Dr. Donald D. Cilla Jr., M.B.A., PharmdCEO, President & Director
  • Mr. Kenneth G. HowlingActing Chief Financial Officer · b. 1958
  • Dr. Gary S. Nabors Ph.D.Chief Development Officer
  • Dr. Carl Gelhaus Ph.D.Director of Non-Clinical Research
  • Mr. Arthur BaranDirector of New Product Development
  • Jenna McNeilCorporate Affairs & Communications Manager

Financials

Income Statement

Currency: CAD2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue000199.11K199.11K1.39M334.18K827.41K100.44K244.18K
Growth (%)----0.00%+598.46%-75.97%+147.60%-87.86%+143.10%
Cost of Revenue10.51K17.67K20.71K-14.84K12.64K6.27K13.66K13.46K8.08K
Gross Profit-10.51K-17.67K-20.71K199.11K-14.84K1.39M327.91K827.41K100.44K236.09K
Gross Margin---100.00%-7.45%100.00%98.12%100.00%100.00%96.69%
Operating Expense3.76M3.75M7.14M6.33M16.28M26.07M8.24M2.99M291.28K6.77M
Operating Income-3.77M-3.77M-7.16M-6.13M-16.30M-24.68M-7.91M-2.16M-190.84K-6.53M
Operating Margin----3079.74%-8184.50%-1774.56%-2368.29%-261.39%-190.00%-2675.64%
EBITDA-2.29M-3.80M-4.93M-5.63M-14.87M-23.51M-8.10M-2.07M360.57K-6.53M
EBITDA Margin----2827.67%-7467.55%-1690.70%-2425.14%-249.78%358.98%-2672.33%
Net Income-1.75M-3.98M-4.33M-5.42M-14.33M-25.12M-9.24M-3.78M-2.62M-4.24M
Net Income Margin----2720.41%-7194.72%-1806.18%-2765.90%-456.96%-2613.12%-1736.73%
R&D2.52M4.95M3.93M3.02M11.49M21.46M3.81M5.62M7.33M4.29M
R&D as % of Total Revenue---1517.09%5771.26%1542.86%1140.03%679.51%7299.95%1757.79%
Interest Expense0208.70K41.48K12.11K69.84K1.55M1.10M1.63M3.50M1.01M
Interest Expense % of Total Revenue---6.08%35.07%111.81%327.99%197.12%3485.44%414.86%

Balance Sheet

Currency: CAD2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets2.57M7.19M6.84M11.17M18.32M8.28M3.13M1.49M3.03M1.97M
Total Liabilities1.19M2.32M2.42M2.33M5.56M11.55M10.53M12.42M16.43M19.30M
Total Equity1.37M4.87M4.42M8.85M12.75M-3.27M-7.40M-10.92M-13.40M-17.33M
Cash1.34M5.72M5.42M10.51M11.06M6.66M2.47M94.49K1.23M40.00K
Total Debt430.00K1.11M1.12M1.00M1.03M4.98M7.67M8.18M12.29M12.94M
Net Debt-910.48K-4.61M-4.30M-9.50M-10.03M-1.69M5.20M8.09M11.07M12.90M

Cash Flow

Currency: CAD2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-2.14M-3.30M-3.46M-4.26M-11.45M-19.08M-10.10M-2.46M868.82K-1.38M
Investing Cash Flow-47.33K-63.22K-13.38K-1.14K-4.99M5.06M-3.17K-29.06K-2.36K-
Financing Cash Flow2.43M7.64M3.06M9.36M17.02M9.56M5.91M122.05K193.68K197.82K
Capital Expenditure37.19K53.05K13.22K1.08K8.45K2.09K3.17K29.72K2.36K5
Free Cash Flow-2.17M-3.36M-3.47M-4.26M-11.46M-19.08M-10.10M-2.49M866.46K-1.38M
Dividends Paid-000000000
FCF to OCF101.74%101.61%100.38%100.03%100.07%100.00%100.03%101.21%99.73%100.00%
Dividend Paid to FCF-0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Earnings

Report DateFeb 27, 2020Jun 24, 2020Aug 14, 2020Nov 13, 2020Feb 15, 2021Jun 24, 2021Aug 13, 2021Nov 12, 2021Feb 14, 2022Jun 29, 2022Aug 12, 2022Nov 10, 2022Feb 14, 2023Jun 23, 2023Aug 11, 2023Nov 13, 2023Feb 12, 2024Jun 25, 2024Aug 13, 2024Nov 14, 2024Feb 14, 2025Jun 23, 2025Aug 19, 2025Nov 20, 2025Feb 19, 2026Jun 29, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate-0.04-0.03-0.05-0.06-0.04-0.06-0.06-0.05-0.09-0.10-0.03-0.03-0.03-0.03-0.02-0.02-0.01-0.01----------
EPS Actual-0.04-0.03-0.05-0.04-0.07-0.08-0.12-0.18-0.05-0.05-0.03-0.01-0.02-0.02-0.01-0.01-0.00-0.01-0.01-0.01-0.000.00-0.01-0.01-0.01-0.01-0.01-
Surprise0.00%0.00%0.00%33.33%-75.00%-33.33%-100.00%-260.00%44.44%50.00%0.00%66.67%33.33%33.33%50.00%50.00%87.00%9.00%----------
TimingAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap661.83K
Enterprise Value14.51M
Trailing P/E0.00
Forward P/E2.38
Price / Sales1.83
Price / Book1.40
EPS-0.03
Book Value-0.144
Revenue (TTM)362.07K
Gross Profit (TTM)362.07K
EBITDA-6.53M
Profit Margin0.00%
Operating Margin-1368.87%
Return on Equity-938.72%
Return on Assets-255.65%
Shares Outstanding132.37M
Shares Float117.93M
Beta-0.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%